.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Optimizing the Treatment of mCRC

EP. 1: Introduction: Bevacizumab Versus Cetuximab in mCRC

July 23rd 2014

EP. 2: CALGB 80405 Trial Results in mCRC

July 23rd 2014

EP. 3: Extended RAS Testing in Metastatic CRC

July 23rd 2014

EP. 4: Conducting Extended RAS Testing in CRC

July 23rd 2014

EP. 5: Future Analyses From the 80405 mCRC Trial

July 23rd 2014

EP. 6: Second-Line Treatment Options in mCRC

July 23rd 2014

EP. 7: BRAF-Mutated Colorectal Cancer

July 23rd 2014

EP. 8: Optimizing Treatment With Regorafenib in mCRC

July 23rd 2014

EP. 9: TAS-102 in Refractory mCRC

July 23rd 2014

EP. 10: Final Thoughts on Optimizing the Treatment of mCRC

July 23rd 2014